Sanofi ADR (SNY) Stock Price

Sanofi ADR Price

NYSE·CLOSED
48.39
​
Market closed

Revenue has compounded at 2.5% per year over the past 19 years to 52.26 B USD. Earnings per share have grown at 4.2% per year over the last 19 years. Sanofi ADR's net margin stands at 16.7%, broadly stable from 15.9% several years earlier. Analysts set a median price target of 49.50 USD, implying 2.3% above the current price. Of 31 analysts, 17 rate the stock a buy — an overall Buy consensus.

Sanofi ADR stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sanofi ADR business model & stock analysis

Sanofi develops and markets therapeutic solutions across immunology, inflammation, rare diseases, neurology, and oncology. It sells pediatric vaccines like poliomyelitis, pertussis, and Hib, alongside respiratory syncytial virus protection and hexavalent combination vaccines covering hepatitis A, typhoid, yellow fever, and rabies. The company collaborates with Exscientia, ABL Bio, and Innate Pharma to develop novel small-molecule drugs and cell engager programs for oncology and immunology. Partnerships with Atomwise, Insilico Medicine, Kymera Therapeutics, Nurix Therapeutics, Denali Therapeutics, and Adagene focus on AI-driven drug discovery and protein degradation therapies targeting immune-inflammatory diseases and cancer. Sanofi's primary buyers are healthcare providers, hospitals, and government health agencies purchasing vaccines and specialty medicines. The company targets segments including pediatric immunization programs, chronic disease management for rare conditions, and oncology treatments. Revenue streams come from direct sales of vaccines and therapeutic products, with additional income from collaboration agreements for drug development, particularly in oncology and immunology. The hexavalent vaccine and pediatric vaccine portfolios are key revenue drivers in global markets. Sanofi's product portfolio includes vaccines such as poliomyelitis, pertussis, Hib, and hexavalent combinations, alongside specialty therapies for neurology and rare diseases. Brands like ABL301 for alpha-synucleinopathies and cell engager programs targeting B7-H3 are developed through partnerships. The company generates revenue through the sale of these products and from licensing agreements with biotech firms, especially in oncology and immunology research. Collaborative development agreements with Exscientia, Kymera, and Nurix contribute significantly to its revenue model.

Frequently asked questions about Sanofi ADR

Analysts currently set an average price target of 49.50 USD for the Sanofi ADR stock (median: 49.50 USD), implying +2.3 % versus the latest price. The consensus is based on 31 analyst ratings.

31 analysts currently rate the Sanofi ADR stock: 17 recommend buying, 13 holding and 1 selling. For 2026, analysts expect Sanofi ADR to generate revenue of 52.51 B USD and earnings per share of 4.45 USD.

Converted at the current exchange rate, the Sanofi ADR share trades at 43.97 EUR (48.39 USD).

The expected revenue of Sanofi ADR is 52.51 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Sanofi ADR is 10.87 B USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Sanofi ADR is currently 10.86. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Sanofi ADR stock.

The price-to-sales ratio (P/S) of Sanofi ADR is currently 2.25. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Sanofi ADR stock.

The Eulerpool Quality Score for Sanofi ADR is 4/10.

The ISIN of Sanofi ADR is US80105N1054. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Sanofi ADR is 662283. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Sanofi ADR is SNY. The ticker symbol is used to trade Sanofi ADR shares on the stock exchange.

Fair ValueTerminal
41.62 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
174,199.14 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website sanofi.com
Currency
USD
Initial public offering
Jul 1, 2002
ISIN
US80105N1054
Cusip
80105N204
Market capitalization
115.83 B USDLarge Cap
52-Week Range
PEG
2.24
P/E ratio
P/Ee 2026
10.66
P/Ee 2027
10.00
P/Ee 2028
9.27
P/Ee 2029
8.49
P/Ee 2030
7.95
P/S
P/Se
2.25
EV/EBIT
12.14
P/B Ratio
1.45
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
8.52 %
Dividend
Dividend yield
0.00 %
Est. Dividend Yield
5.01 %
Payout Ratio
0.00 %
Dividend growth Ø5Y
—
Dividend payments per year
1
Dividend paid since
1 year+
Dividend not reduced since
0 years
Dividend increased since
0 years
Dividend withholding tax
30.00 %
Last updated Nov 17, 2026, 12:14 PM

Sanofi ADR Peer Group

All fundamentals and in-depth analysis of Sanofi ADR

Our stock analysis for Sanofi ADR stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sanofi ADR. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.